3D microfluidic tumor cell/tissure array (3D uFC/TA) chip for the detection of clinical drug sensitivity of hepatoblastoma

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000035670

Enrollment

Unknown

Registered

2020-08-16

Start date

2020-10-01

Completion date

Unknown

Last updated

2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatoblastoma

Interventions

Case series:Nil

Eligibility

Sex/Gender

All

Age

No minimum to 15 Years

Inclusion criteria

Inclusion criteria: 1. Aged 0 to 15 years old; 2. The tumor is histologically classified according to WHO standards, and the tumor staging is according to TNM staging; 3. Without chemotherapy or other medications before surgery.

Exclusion criteria

Exclusion criteria: 1. Does not meet the selection criteria of the above groups; 2. There are few tissue specimens, only enough specimens for clinical diagnosis; 3. Patients are unwilling to conduct follow-up studies.

Design outcomes

Primary

Measure	Time frame
Tumor drug sensitivity index (SI);	—

Countries

China

Contacts

Public ContactPan Qiuhui

Department of Laboratory Medicine Shanghai Children's Medical Center

panqiuhui@scmc.com.cn+86 18917683891

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026